ClinicalTrials.gg
RecruitingNCT06222697Updated Jun 22, 2026

A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A

An observational study in Hemophilia A, Prophylaxis of Bleeding and Treatment of Bleeding, sponsored by Bayer. Recruiting at 1 site in South Korea. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Bayer · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Hemophilia A by Bayer — 3 open to participants now, 6 under way, none of them phase 3. Hemophilia A · Bayer.

Planned enrollment
23rd of 26
20 · median 67
Started
2024
the only one that year
Observational
26 of 57
3 open now
Registered
55th of 57
by date

Among the 57 studies in Hemophilia A by Bayer, this one is the 23rd largest by planned enrollment of the 26 observational ones that give a count, is the only one that started in 2024, is one of 26 observational ones, and was the 55th registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

3 of the 57 studies in Hemophilia A by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hemophilia A by Bayer, or all of them as a file.
02

Study summary

In this study, researchers will observe and study the data from participants with hemophilia A who receive damoctocog alfa pegol as prescribed by their doctors. Participants will not receive any advice or changes to their healthcare during the study.

Hemophilia A is a genetic bleeding disorder. It is caused by the lack of a protein called clotting factor 8 (FVIII) that helps blood to clot properly. Lack of FVIII can result in excessive blood loss or bleeding inside the body after being injured or having surgery.

The study drug, damoctocog alfa pegol, can be used to prevent or treat bleeding episodes by replacing missing FVIII in the body of people with hemophilia A. It is already approved for people with hemophilia A who are at least 12 years old and have previously used other hemophilia A treatments.

Through this study, researchers want to learn more about its safety in a real-world setting.

The participants will receive damoctocog alfa pegol as prescribed by their doctors during routine practice according to the approved product information.

The main purpose of this study is to learn more about how safe damoctocog alfa pegol is in Korean participants with hemophilia A who previously used other hemophilia A treatments. To do this, researchers will collect information about any medical problems participants have during their treatment.

Data will be collected from December 2023 to March 2026 and cover a period of about 8 months for each participant. Data will come from participants' health records and information collected during their routine clinic visits.

In this study, only available data from routine care will be collected. No visits or tests are required as part of this study.

03

Conditions studied

  • Hemophilia A
  • Prophylaxis of Bleeding
  • Treatment of Bleeding

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study should be conduct on hemophilia A patients who are prescribed with Jivi (damoctocog alfa pegol) as sole treatment for an approved indication (the treatment and prophylaxis of bleeding in PTPs aged ≥ 12 years with hemophilia A (congenital FVIII deficiency)) by the Ministry of Food and Drug Safety (MFDS) in Korea.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥12 years of age with hemophilia A
  • Previously treated with FVIII concentrate(s) (plasma derived or recombinant)
  • Patients who have been treated with Jivi (damoctocog alfa pegol) and those for whom the decision to initiate treatment with Jivi was made as per physician's routine treatment practice with any kind of treatment modality (on-demand, prophylaxis, etc.)
  • Written from subject or legal representative; assent from subject when appropriate

Exclusion criteria

Exclusion Criteria:

  • according to the local authorized indication (including known to the drug substance or any of its components (e.g., mouse or hamster protein))
  • Patients participating in an program with interventions outside of routine clinical practice
  • Patients with any other diagnosis of bleeding/coagulation disorder other than hemophilia A
  • Patients on immune tolerance induction treatment at the time of enrollment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Post-marketing surveillance cohort

    Participants follow their usual medical visits with data collection occurs continuously in a 36-week observational period.

    Drug: Damoctocog-alfa-pegol (Jivi, BAY94-9027)

Interventions

06

What researchers measure

Primary outcomes

  1. Occurrence of adverse events (AEs)

    Number of participants with AEs

    Time frame: Up to 36 weeks

  2. Occurrence of Serious adverse events (SAEs)

    Number of participants with SAEs

    Time frame: Up to 36 weeks

  3. Occurrence of adverse reactions (ARs)

    Number of participants with ARs

    Time frame: Up to 36 weeks

  4. Occurrence of Serious adverse reactions (SARs)

    Number of participants with SARs

    Time frame: Up to 36 weeks

  5. Occurrence of adverse events of important identified risks (AESIs)

    Important identified risks include development of Factor VIII inhibitors/Hypersensitivity/Clinical response characterised by lack of drug effect associated with anti-polyehtylene glycol (PEG) antibodies.

    Time frame: Up to 36 weeks

  6. Number of adverse events related to overdose

    Time frame: Up to 36 weeks

  7. Number of adverse events related to previously taken drugs and concomitant drugs

    Time frame: Up to 36 weeks

Secondary outcomes

  1. Annualized number of reported total bleeds

    Time frame: Up to 36 weeks

  2. Difference in annualized total number of injections, injection frequency from previous FVIII products versus Jivi (damoctocog alfa pegol)

    Time frame: Up to 36 weeks

  3. Difference annualized total/average factor consumption (for overall, prophylaxis, bleeds(Intermittent prophylaxis), and other events) from previous FVIII products versus Jivi (damoctocog alfa pegol)

    Time frame: Up to 36 months

  4. Regimen selection determinants (physician and patient)

    Time frame: Up to 36 weeks

  5. Number of patients with 0 bleeds, and the difference in proportion comparing to previous prophylaxis treatment

    Time frame: Up to 36 weeks

  6. ABR during the study compared with ABR for previous FVIII products in the 12 months prior to enrollment into the study

    ABR stands for annualized bleeding rate.

    Time frame: Up to 36 weeks

07

Study locations

1 of 1 sites recruiting
  • Many Locations
    Multiple Locations, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Mar 2028, 50 months after the start.

Of 53 industry-sponsored observational studies under Hemophilia A, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 79. This study's planned 50 months is below that.

Counting every sponsor, half of 131 studies reached it within 45 months; a quarter within 25 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 25, 2024
StartActual
Jan 24, 2024
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06222697
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 25, 2024
Start date
Jan 24, 2024
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Jun 22, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
(+)1-888-84 22937

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion